title: Ligands for the Nuclear Peroxisome Proliferator-Activated Receptor Gamma.
abstract: Nuclear receptors are ligand-activated transcription factors, which represent a primary class of drug targets. The nuclear receptor peroxisome proliferator-activated receptor gamma (PPARγ) is a key player in various biological processes. PPARγ is widely known as the target protein of the thiazolidinediones for treating type 2 diabetes. Moreover, PPARγ ligands can induce anti-inflammatory and potentially additional beneficial effects. Recent mechanistic insights of PPARγ modulation give hope the next generation of efficient PPARγ-based drugs with fewer side effects can be developed. Furthermore, chemical approaches that make use of synergistic action of combinatorial ligands are promising alternatives for providing tailored medicine. Lessons learned from fine-tuning the action of PPARγ can provide avenues for efficient molecular intervention via many other nuclear receptors to combat common diseases.
authors.affiliation: Otto-Warburg Laboratory, Max Planck Institute for Molecular Genetics, Ihnestrasse 73, 14195 Berlin, Germany; University of Würzburg, CU Systems Medicine, Josef-Schneider-Straße 2, Building D15, 97070 Wuerzburg, Germany. Electronic address: sauer@molgen.mpg.de.
authors.forename: Sascha
authors.initials: S
authors.lastname: Sauer
mesh_terms: D000818:Animals; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000737:chemistry / Q000494:pharmacology*; D008024:Ligands; D047495:PPAR gamma / Q000819:agonists / Q000037:antagonists & inhibitors / Q000737:chemistry / Q000378:metabolism*; D011485:Protein Binding; D045162:Thiazolidinediones / Q000009:adverse effects / Q000737:chemistry / Q000494:pharmacology*
chemical_list: D007004:Hypoglycemic Agents; D008024:Ligands; D047495:PPAR gamma; D045162:Thiazolidinediones